EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study

Yusuke Kashiwado iD, Yasutaka Kimoto, Takuya Sawabe, Kensuke Irino, Shota Nakano, Junki Hiura, Qiaolei Wang, Shotaro Kawano, Masahiro Ayano, Hiroki Mitoma, Nobuyuki Ono, Yojiro Arinobu und 7 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac030 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yusuke Kashiwado und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan. Hauptthemen laut MEDLINE: COVID-19, Rheumatic Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan College of Rheumatology (Jcr).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the impact of medication on antibody response to severe acute respiratory syndrome coronavirus-2 mRNA vaccines in Japanese patients with rheumatic diseases.

Methods

This prospective multicentre cohort study evaluated the humoral response in 12 different medication groups. Antibody levels before the first vaccination and 3–6 weeks after the second vaccination were measured using the Elecsys Anti-SARS-CoV-2 S assay. Statistical analysis included comparing antibody titres among the different medication groups using the Kruskal–Wallis test followed by the Bonferroni–Dunn test and multiple linear regression analysis.

Results

295 patients were analysed. The seroconversion rate was 92.2% and the median antibody titre was 255 U/ml (interquartile range, 34.1–685) after the second mRNA vaccination. Antibody levels were significantly lower in the groups treated with Tumour necrosis factor inhibitor with methotrexate, abatacept, mycophenolate mofetil (MMF), MMF or mizoribine combined with calcineurin inhibitor, and rituximab or cyclophosphamide compared with those treated with sulfasalazine and/or bucillamine or calcineurin inhibitor (p < 0.01). The correlation between antibody titre and treatment was significant after adjusting for age, gender, and glucocorticoid dose (p < 0.01).

Conclusions

Additional early vaccination is required in patients treated with Tumour necrosis factor inhibitor and methotrexate, abatacept, MMF, MMF or mizoribine combined with calcineurin inhibitor and rituximab or cyclophosphamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Rheumatic DiseasesHumansImmunosuppressive AgentsRituximabMethotrexateAbataceptCalcineurin InhibitorsJapanAntibody FormationCOVID-19 VaccinesProspective StudiesCohort StudiesTumor Necrosis Factor InhibitorsSARS-CoV-2Mycophenolic AcidCyclophosphamide

Stichwörter der Autor:innen

COVID-19 vaccinesRheumatic diseasesantirheumatic agentsimmunosuppressive agents

Substanzen

Immunosuppressive AgentsRituximabMethotrexateAbataceptCalcineurin InhibitorsCOVID-19 VaccinesTumor Necrosis Factor InhibitorsMycophenolic AcidCyclophosphamide

Autor:innen und Institutionen

  • Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan.
  • Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
  • Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Medical Education, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Clinical Research, Rheumatology and Allergology, Osaka Minami Medical Center, Osaka, Japan.

ORCID-Profile: Yusuke Kashiwado, Shiro Ohshima

Förderung

  • Japan College of Rheumatology (Jcr)

Zitieren

APA

Kashiwado, Y., Kimoto, Y., Sawabe, T., Irino, K., Nakano, S., Hiura, J., Wang, Q., Kawano, S., Ayano, M., Mitoma, H., Ono, N., Arinobu, Y., Niiro, H., Hotta, T., Kang, D., Akashi, K., Ohshima, S., Takeuchi, T., & Horiuchi, T. (2023). Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roac030

Vancouver

Kashiwado Y, Kimoto Y, Sawabe T, Irino K, Nakano S, Hiura J, et al. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. Modern Rheumatology. 2023. doi:10.1093/mr/roac030

BibTeX
@article{Kashiwado2023,
  author = {Kashiwado, Yusuke and Kimoto, Yasutaka and Sawabe, Takuya and Irino, Kensuke and Nakano, Shota and Hiura, Junki and Wang, Qiaolei and Kawano, Shotaro and Ayano, Masahiro and Mitoma, Hiroki and Ono, Nobuyuki and Arinobu, Yojiro and Niiro, Hiroaki and Hotta, Taeko and Kang, Dongchon and Akashi, Koichi and Ohshima, Shiro and Takeuchi, Tsutomu and Horiuchi, Takahiko},
  title = {Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac030}
}
Kostenlos starten →